6 hours Ago By Defense World Staff
HC Wainwright reiterated their buy rating on shares of ALX Oncology ( NASDAQ:ALXO – Free Report ) in a research report released on Wednesday morning, Benzinga reports. The firm currently has a $25.00 price objective on the stock.
Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a research note on Tuesday, November 12th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.
com, the company has a consensus rating of “Moderate Buy” and an average target price of $8.50. Check Out Our Latest Stock Analysis on ALXO ALX Oncology Price Performance Insider Transactions at ALX Oncology In other news, Director Rekha Hemrajani bought 30,000 shares of the company’s stock in a transaction dated Monday, December 2nd.
The shares were acquired at an average cost of $1.55 per share, with a total value of $46,500.00.
Following the completion of the transaction, the director now directly owns 33,000 shares in the company, valued at approximately $51,150. The trade was a 1,000.00 % increase in their position.
The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link . 33.40% of the stock is owned by insiders.
Institutional Investors Weigh In On ALX Oncology Several hedge funds have recently made changes to their positions in the company. Marshall Wace LLP grew its position in ALX Oncology by 423.0% during the 2nd quarter.
Marshall Wace LLP now owns 635,679 shares of the company’s stock worth $3,833,000 after purchasing an additional 514,133 shares in the last quarter. Privium Fund Management B.V.
boosted its position in shares of ALX Oncology by 28.2% in the third quarter. Privium Fund Management B.
V. now owns 509,059 shares of the company’s stock worth $926,000 after buying an additional 112,093 shares during the period. Renaissance Technologies LLC grew its holdings in shares of ALX Oncology by 87.
2% during the second quarter. Renaissance Technologies LLC now owns 438,200 shares of the company’s stock valued at $2,642,000 after buying an additional 204,100 shares in the last quarter. XTX Topco Ltd acquired a new position in ALX Oncology during the third quarter valued at $578,000.
Finally, Point72 Asset Management L.P. purchased a new stake in ALX Oncology in the 2nd quarter worth about $1,834,000.
Hedge funds and other institutional investors own 97.97% of the company’s stock. About ALX Oncology ( Get Free Report ) ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.
The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. See Also Five stocks we like better than ALX Oncology What is the Nikkei 225 index? Opal Fuels CEO on Steering the Future of Renewable Natural Gas What is a Dividend King? MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win Why Understanding Call Option Volume is Essential to Successful Options Trading 2 Underrated Quantum Computing Companies Starting to Rally Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter .
.
